Dapt Calculator - PCI Therapy Duration

A DAPT calculator turns the nine published rules from the Dual Antiplatelet Therapy study into a -2 to 10 total that helps a clinician decide whether to keep a patient on dual antiplatelet therapy beyond 12 months after a percutaneous coronary intervention (PCI) with stents.

• • 12-month DAPT review: A cardiology clinic visit at 12 months after PCI, when the team decides whether to stop the P2Y12 inhibitor or continue through 30 months.
• • Borderline bleeding and ischemic risk: A patient with prior GI bleeding, older age, or a recent stent whose net trade-off is not obvious from the chart.
• • Teaching and protocol review: Trainees or pharmacists learning the published DAPT trial rules and the two-band decision tool.
• • Documentation and quality work: A structured record of the nine factors at the 12-month decision, useful for protocol audits and chart notes.

DAPT is the combination of aspirin and a P2Y12 inhibitor (clopidogrel, prasugrel, or ticagrelor) given after PCI to prevent stent thrombosis, recurrent MI, and stroke. After 12 months the marginal ischemic benefit of continuing the combination shrinks while the cumulative bleeding risk keeps rising, so the 12-month visit is a natural decision point.

When the visit also includes a primary-prevention conversation, the CVD Risk Calculator converts the same lipid and blood pressure panel into a 10-year cardiovascular risk percentage that frames the patient's underlying risk.

The DAPT calculator applies each of the nine published rules, sums the points that fire, and pairs the integer total with a two-band interpretation. The total can range from -2 to +10, and the same threshold rule applies to every patient: 2 or more favors continuing the combination, 1 or less favors stopping at 12 months.

• agePoints: Under 65 = 0, 65 to 75 = -1, 75 or older = -2.
• diabetes: 1 point if diabetes is present at the index PCI.
• smoker: 1 point for current or recent smoking.
• priorPciOrMi: 1 point for prior PCI or MI.
• miAtPresentation: 1 point for MI as the index event.
• smallStent: 1 point for any stent under 3 mm.
• veinGraftStent: 2 points for a stent in a saphenous vein graft.
• paclitaxelStent: 1 point for a paclitaxel-eluting stent.
• chfOrLvefLow: 2 points for CHF or LVEF below 30%.

The result panel shows the integer total, the two-band decision directly under it, and the per-factor sub-scores so the reviewer can see which rule fired.

According to Yeh et al. 2016, JAMA (DAPT Study), the DAPT score was developed and validated in 11,648 randomized patients from the DAPT study and identifies patients who benefit from versus are harmed by continuing dual antiplatelet therapy beyond 12 months after percutaneous coronary intervention.

When bleeding is the main concern, the CRCL Calculator returns a Cockcroft-Gault creatinine clearance the team uses to titrate the P2Y12 dose and weight the bleeding risk, since reduced clearance is a bleeding signal the DAPT rules do not capture.

Four ideas explain why a small set of yes/no questions, plus an age band, returns a single integer that maps to a treatment recommendation.

These patterns show up in the trial's high-score and low-score groups and are the same patterns the calculator reproduces. The 12-month visit is a sensible place to read the score: the question is no longer 'should this patient get DAPT' but whether the net trade-off still favors keeping the combination for another 18 months.

Lipid control drives the ischemic half of the DAPT trade-off, and the LDL Calculator reads the same fasting lipid panel drawn at the 12-month review into the LDL value that sets statin intensity.

Treat the DAPT calculator as a structured review for the 12-month visit. Work through the nine rules in any order.

1. 1 Set the age band: Pick the band that matches the patient. Under 65 is 0, 65 to 75 is -1, 75 or older is -2.
2. 2 Capture the clinical risk flags: Mark diabetes, smoking, prior PCI or MI, and MI at presentation. Each is worth 1 point.
3. 3 Capture the procedural and device flags: Mark whether a stent is under 3 mm, whether a vein graft was stented (2 points), and whether a paclitaxel-eluting stent was used (1 point).
4. 4 Capture the heart-failure flag: Mark whether there is CHF or an LVEF under 30%. This is the second 2-point contributor.
5. 5 Read the total and the band: Add the sub-scores and read the total against the two bands. 2 or more favors prolonged DAPT; 1 or less favors stopping the P2Y12 inhibitor at 12 months.
6. 6 Document and individualize: Record the total and the band in the chart note, and use it as one input to the final duration decision.

A 72-year-old with a vein graft stent, diabetes, and prior PCI: age band -1, diabetes 1, prior PCI 1, vein graft stent 2, rest 0. Total = 3, so the band reads 'Prolonged DAPT'.

Antiplatelet choice and bleeding risk both depend on kidney function, so the GFR Calculator is the natural next stop in the chart for the serum creatinine and cystatin C pair that the team runs alongside the 12-month DAPT review.

The DAPT score is a published trial-based tool, and a calculator makes the tally consistent, traceable, and easier to defend in the chart note.

• • Trial-anchored decision: The score is built from 11,648 randomized patients in the DAPT study and is cited by the 2016 ACC/AHA and 2017 ESC focused updates.
• • Standardized review across providers: Pharmacists, cardiologists, and trainees use the same nine rules.
• • Transparent record-keeping: Each sub-score and the total can be quoted in the chart note.
• • Quick link to the two-band rule: The calculator pairs the total with the published two-band rule.
• • Works for borderline cases: When the visit is on the fence, the sub-score panel makes it easy to see which rule is pushing the total above or below 2.

Pair the score with a quick kidney function review, a recent hemoglobin, and the patient's own bleeding history, and the result becomes a record-organizing aid.

Blood pressure control is the other pillar of post-PCI secondary prevention, and the Blood Pressure Calculator classifies the same office cuff reading the team weighs against the ischemic and bleeding profile at the 12-month DAPT review.

Several things move the total up or down, and a few clinical situations are not captured by the nine rules.

• • The DAPT score is a structured aid, not a prescription. The 2016 ACC/AHA focused update describes the score as one tool that may be reasonable for individualization.
• • The score was derived in patients who had completed 12 months of DAPT, so it is meant for the 12-month review rather than the immediate post-PCI period.
• • Bleeding risk factors that often matter in practice (prior GI bleed, oral anticoagulation, chronic kidney disease, low hemoglobin) are not part of the nine rules.

A high score in a patient with a recent major bleed still needs a clinician override, and a low score in a patient with a high ischemic risk profile still needs a documented reason to extend therapy.

According to 2016 ACC/AHA DAPT focused update (Circulation), the DAPT score may be reasonable to use as a clinical decision tool to identify patients who may benefit from extended DAPT duration beyond 12 months after PCI.

According to 2017 ESC focused update on DAPT, the DAPT score can support a more individualized decision on the duration of dual antiplatelet therapy in patients who have completed 12 months of treatment after PCI.

Residual atherogenic burden is another piece of context the DAPT rules do not capture, and the Cholesterol Ratio Calculator reads the same total-cholesterol and HDL pair the team tracks over time to gauge modifiable ischemic risk.